Evolving issues in the management of reflux disease?

Current Opinion in Gastroenterology

Volumn 25, Issue 4, 2009, Pages 342-351

  Yuan, Yuhong ^a   Hunt, Richard H ^a  

^a MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

Author keywords

Acid exposure; Gastroesophageal reflux disease; Nocturnal; Proton pump inhibitor failure

Indexed keywords

8 (2,6 DIMETHYLBENZYLAMINO) N (2 HYDROXYETHYL) 2,3 DIMETHYLIMIDAZO[1,2 A]PYRIDINE 6 CARBOXAMIDE; ADX 10059; AGN 201904Z; AZD 3355; AZD 9343; BENATOPRAZOLE; CS 526; ESOMEPRAZOLE; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PLACEBO; POTASSIUM COMPETITIVE ACID BLOCKER; PROTON PUMP INHIBITOR; PUMOSETRAG; RABEPRAZOLE; REVAPRAZAN; SEROTONIN AGONIST; SORAPRAZAN; STOMACH SECRETION INHIBITOR; TEGASEROD; UNCLASSIFIED DRUG; VB 101; XP 19986;

BARRETT ESOPHAGUS; BEDTIME DOSAGE; CLINICAL TRIAL; DELAYED RELEASE FORMULATION; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG INHIBITION; DRUG MEGADOSE; DRUG RELEASE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ESOPHAGUS BIOPSY; ESOPHAGUS MUCOSA; ESOPHAGUS PH; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL ENDOSCOPY; HEARTBURN; HELICOBACTER PYLORI; HUMAN; MORNING DOSAGE; PATHOGENESIS; PATIENT COMPLIANCE; REFLUX ESOPHAGITIS; REVIEW; STOMACH PH; SYMPTOM; SYMPTOMATOLOGY; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE;

ANTI-ULCER AGENTS; DELAYED-ACTION PREPARATIONS; DRUG RESISTANCE; DRUGS, INVESTIGATIONAL; ESOPHAGEAL PH MONITORING; ESOPHAGITIS, PEPTIC; ESOPHAGOSCOPY; FEMALE; FOLLOW-UP STUDIES; GASTRIC ACIDITY DETERMINATION; GASTRIC MUCOSA; GASTROESOPHAGEAL REFLUX; HUMANS; MALE; PROTON PUMP INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 68049104246     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOG.0b013e32832c1504     Document Type: Review

References (106)

1. Sharma P, Wani S, Romero Y, et al. Racial and geographic issues in gastroesophageal reflux disease. Am J Gastroenterol 2008; 103:2669-2680. This article systematically reviews the epidemiology, pathophysiology, diagnosis, and treatment between various racial and geographic groups and suggests that the study of multicultural issues in GERD should be considered.
2. El-Serag HB. Time trends of gastroesophageal reflux disease: a systematic review. Clin Gastroenterol Hepatol 2007; 5:17-26.
3. Dent J, Kahrilas PJ, Vakil N, et al. Clinical trial design in adult reflux disease: a methodological workshop. Aliment Pharmacol Ther 2008; 28:107-126. A methodological workshop developed some consensus statements to inform about clinical trial design in adult patients with GERD. (Pubitemid 351782809)
4. Fass R, Sifrim D. Management of heartburn not responding to proton pump inhibitors. Gut 2009; 58:295-309. This review discusses various underlying mechanisms, which contribute to the failure of PPIs and how to manage refractory heartburn.
5. Chey WD, Mody R, Kothari S, et al. Are proton pump inhibitors (PPIs) sufficient in controlling symptoms of gastro-esophageal reflux disease (GERD)? A community-based US survey study. Gastroenterology 2008; 134 (Suppl 1):A-325; Abstract #M1041.
6. Armstrong D, Marshall JK, Chiba N, et al., Canadian Association of Gastroenterology GERD Consensus Group. Canadian Consensus Conference on the management of gastroesophageal reflux disease in adults - update 2004. Can J Gastroenterol 2005; 19:15-35.
7. Modlin IM, Hunt RH, Malfertheiner P, et al. Nonerosive reflux disease - defining the entity and delineating the management. Digestion 2008; 78 (Suppl 1):1-5. The recent NERD Task Force consensus statement for the definition of NERD, clinical presentation, assessment of disease outcome, pathobiological mechanisms, and management strategies for NERD.
8. Fass R. Nonerosive reflux disease (NERD) and erosive esophagitis - a spectrum of disease or special entities? Z Gastroenterol 2007; 45:1156-1163.
9. Galmiche JP, Clouse RE, Bálint A, et al. Functional esophageal disorders. Gastroenterology 2006; 130:1459-1465.
10. Savarino E, Zentilin P, Tutuian R, et al. The role of nonacid reflux in NERD: lessons learned from impedance-pH monitoring in 150 patients off therapy. Am J Gastroenterol 2008; 103:2685-2693. This study reviews the role of impedance and pH monitoring for nonacid reflux in patients with NERD.
11. Winter JW, Heading RC. The nonerosive reflux disease-gastroesophageal reflux disease controversy. Curr Opin Gastroenterol 2008; 24:509-515.
12. Falk GW. Is conventional endoscopic identification of nonerosive reflux disease adequate? Digestion 2008; 78 (Suppl 1):17-23.
13. Miwa H, Yokoyama T, Hori K, et al. Interobserver agreement in endoscopic evaluation of reflux esophagitis using a modified Los Angeles classification incorporating grades N and M: a validation study in a cohort of Japanese endoscopists. Dis Esophagus 2008; 21:355-363. (Pubitemid 351663453)
14. Lee JH, Kim N, Chung IK, et al. Clinical significance of minimal change lesions of the esophagus in a healthy Korean population: a nationwide multicenter prospective study. J Gastroenterol Hepatol 2008; 23 (7 Pt 1):1153-1157. (Pubitemid 352019377)
15. Dent J. Endoscopic grading of reflux oesophagitis: the past, present and future. Best Pract Res Clin Gastroenterol 2008; 22:585-599. A review of the endoscopic classification and grading of reflux esophagitis. (Pubitemid 352016338)
16. Vieth M. Structural abnormalities of endoscopy-negative reflux disease - real or perceived? Digestion 2008; 78 (Suppl 1):24-30.
17. Tytgat GN. The value of esophageal histology in the diagnosis of gastroesophageal reflux disease in patients with heartburn and normal endoscopy. Curr Gastroenterol Rep 2008; 10:231-234.
18. Caviglia R, Ribolsi M, Gentile M, et al. Dilated intercellular spaces and acid reflux at the distal and proximal oesophagus in patients with nonerosive gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2007; 25:629-636. (Pubitemid 46255856)
19. Farré R, van Malenstein H, De Vos R, et al. Short exposure of oesophageal mucosa to bile acids, both in acidic and weakly acidic conditions, can impair mucosal integrity and provoke dilated intercellular spaces. Gut 2008; 57:1366-1374. An animal experiment suggesting that short exposure of the esophageal mucosa to bile acids, both in acidic and weakly acidic conditions, impairs esophageal mucosal integrity and induces DISs.
20. Ribolsi M, Caviglia R, Gentile M, et al. Dilated intercellular space diameters of esophageal epithelium in NERD patients with typical symptoms resistant to PPI therapy. Gastroenterology 2007; 132 (4 Suppl 2):A139; Abstract #935.
21. van Malenstein H, Farré R, Sifrim D. Esophageal dilated intercellular spaces (DIS) and nonerosive reflux disease. Am J Gastroenterol 2008; 103:1021-1028. A comprehensive review of the evidence and possible relationship between DISs and NERD.
22. Wang C, Hunt RH. Precise role of acid in nonerosive reflux disease. Digestion 2008; 78 (Suppl 1):31-41. A review of the precise role of acid in NERD and the pathogenesis of heartburn in NERD.
23. Xiong ZG, Pignataro G, Li M, et al. Acid-sensing ion channels (ASICs) as pharmacological targets for neurodegenerative diseases. Curr Opin Pharmacol 2008; 8:25-32. (Pubitemid 351168687)
24. Wultsch T, Painsipp E, Shahbazian A, et al. Deletion of the acid-sensing ion channel ASIC3 prevents gastritis-induced acid hyperresponsiveness of the stomach-brainstem axis. Pain 2008; 134:245-253.
25. Hunt RH, Armstrong D, Yaghoobi M, et al. Predictable prolonged suppression of gastric acidity with a novel proton pump inhibitor, AGN 201904-Z. Aliment Pharmacol Ther 2008; 28:187-199. The first published phamacodynamic and pharmacokinetic study of AGN 201904-Z in humans. (Pubitemid 351861964)
26. Dean BB, Gano AD Jr, Knight K, et al. Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol 2004; 2:656-664. (Pubitemid 39013424)
27. Fass R. Erosive esophagitis and nonerosive reflux disease (NERD): comparison of epidemiologic, physiologic, and therapeutic characteristics. J Clin Gastroenterol 2007; 41:131-137. (Pubitemid 46148652)
28. El-Serag HB. Epidemiology of nonerosive reflux disease. Digestion 2008; 78 (Suppl):6-10.
29. Shaker R, Castell DO, Schoenfeld PS, Spechler SJ. Nighttime heartburn is an under-appreciated clinical problem that impacts sleep and daytime function: the results of a Gallup survey conducted on behalf of the American Gastroenterological Association. Am J Gastroenterol 2003; 98:1487-1493. (Pubitemid 36875337)
30. Tytgat GN. Are there unmet needs in acid suppression? Best Pract Res Clin Gastroenterol 2004; 18 (Suppl):67-72.
31. Bell NJ, Burget D, Howden CW, et al. Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion 1992; 51 (Suppl 1):59-67.
32. Smith JL, Opekun AR, Larkai E, Graham DY. Sensitivity of the esophageal mucosa to pH in gastroesophageal reflux disease. Gastroenterology 1989; 96:683-689. (Pubitemid 19057588)
33. Grigolon A, Cantù P, Savojardo D, et al. Esophageal acid exposure on proton pump inhibitors in unselected asymptomatic gastroesophageal reflux disease patients. J Clin Gastroenterol 2008; 42:969-973.
34. Gerson LB, Boparai V, Ullah N, Triadafilopoulos G. Oesophageal and gastric pH profiles in patients with gastro-oesophageal reflux disease and Barrett's oesophagus treated with proton pump inhibitors. Aliment Pharmacol Ther 2004; 20:637-643. (Pubitemid 39279052)
35. Ribolsi M, Emerenziani S, Caviglia R, et al. Short duration of acid exposure sensitizes the esophagus to perception of weakly acidic and mixed reflux in nonerosive reflux disease (NERD) patients. Gastroenterology 2008; 134 (4, Suppl 1):A593; Abstract #T1984.
36. Wang CC, Yuan Y, Chen Y, Hunt RH. Night-time pH holding time: what is hidden by the % of time pH ≤ 4? Am J Gastroenterol 2008; 103 (Suppl 1): S51; Abstract #130.
37. Johnson LF, Demeester TR. Twenty-four-hour pH monitoring of the distal esophagus. A quantitative measure of gastroesophageal reflux. Am J Gastroenterol 1974; 62:325-332.
38. Gardner JD, Rodriguez-Stanley S, Robinson M. Integrated acidity and the pathophysiology of gastroesophageal reflux disease. Am J Gastroenterol 2001; 96:1363-1370. (Pubitemid 32455060)
39. Gardner JD, Sloan S, Miner PB, Robinson M. Determination of the reduction in gastric acidity necessary to prevent pathological oesophageal reflux in patients with gastro-oesophageal reflux disease treated with a proton pump inhibitor. Aliment Pharmacol Ther 2003; 17:955-964. (Pubitemid 36459608)
40. Gerson LB, Triadafilopoulos G, Sahbaie P, et al. Time esophageal pH < 4 overestimates the prevalence of pathologic esophageal reflux in subjects with gastroesophageal reflux disease treated with proton pump inhibitors. BMC Gastroenterol 2008; 8:15. (Pubitemid 351803134)
41. Avidan B, Sonnenberg A, Schnell TG, Sontag SJ. Acid reflux is a poor predictor for severity of erosive reflux esophagitis. Dig Dis Sci 2002; 47:2565-2573. (Pubitemid 35305467)
42. El-Serag H. The association between obesity and GERD: a review of the epidemiological evidence. Dig Dis Sci 2008; 53:2307-2312. This article reviews the results of a recent meta-analysis and epidemiological data and suggests that obesity satisfies several criteria for a causal association with GERD and some of its complications. In addition, maintaining a normal BMI may reduce the likelihood of developing GERD and its potential complications.
43. Kim N, Lee SW, Cho SI, et al. The prevalence of and risk factors for erosive oesophagitis and nonerosive reflux disease: a nationwide multicentre prospective study in Korea. Aliment Pharmacol Ther 2008; 27:173-185. (Pubitemid 350256608)
44. Hobson AR, Furlong PL, Aziz Q. Oesophageal afferent pathway sensitivity in nonerosive reflux disease. Neurogastroenterol Motil 2008; 20:877-883. This investigation studied NERD and matched controls and provided objective evidence that increased esophageal pain sensitivity in reflux negative NERD is associated with heightened afferent sensitivity. (Pubitemid 352019714)
45. Kahrilas PJ, Shaheen NJ, Vaezi MF, et al., American Gastroenterological Association. American Gastroenterological Association Medical Position Statement on the management of gastroesophageal reflux disease. Gastroenterology 2008; 135:1383-1391; 1391.e1-5 The AGA statement for the management of GERD in 2008.
46. Raghunath AS, Hungin AP, Mason J, Jackson W. Symptoms in patients on long-term proton pump inhibitors: prevalence and predictors. Aliment Pharmacol Ther 2009; 29:431-439.
47. Yuan Y, Wang CC, Yuan Y, Hunt RH. The proportion of patients who are free of reflux symptoms during the initial days of treatment with proton pump inhibitors (PPIs) in GERD trials: a meta-analysis. Gastroenterology 2008; 134 (4, suppl 1):A174; Abstract #S1085.
48. Yuan Y, Vinh B, Hunt RH. Nonhealed rate of moderate-severe (LA Classification Grade C and D) erosive esophagitis after 4-8 weeks proton pump inhibitors (PPIs): evidence of an unmet need. Gastroenterology 2009; 136 (Suppl) (Abstract #M1893.).
49. Howden CW, Burget DW, Hunt RH. Appropriate acid suppression for optimal healing of duodenal ulcer and gastro-oesophageal reflux disease. Scand J Gastroenterol Suppl 1994; 201:79-82.
50. Hunt RH. Importance of pH control in the management of GERD. Arch Intern Med 1999; 159:649-657.
51. Yuan Y, Hunt RH. Intragastric pH holding time pH <3 at steady state in healthy volunteers (HV) after once daily PPIs: a predictor for low erosive esophagitis (EE) healing rates? Gastroenterology 2009; 136 (Suppl) Abstract #M1900.
52. Karamanolis G, Vanuytsel T, Sifrim D, et al. Yield of 24-h esophageal pH and bilitec monitoring in patients with persisting symptoms on PPI therapy. Dig Dis Sci 2008; 53:2387-2393.
53. Yuan Y, Hunt RH. Intragastric acid suppressing effect of proton pump inhibitors twice daily at steady state in healthy volunteers: evidence of an unmet need? Am J Gastroenterol 2008; 103 (Suppl 1):S50; Abstract #128.
54. Orr WC. Reflux events and sleep: are we vulnerable? Curr Gastroenterol Rep 2006; 8:202-207.
55. Richter JE. The patient with refractory gastroesophageal reflux disease. Dis Esophagus 2006; 19:443-447. (Pubitemid 44644679)
56. Richter JE. How to manage refractory GERD. Nat Clin Pract Gastroenterol Hepatol 2007; 4:658-664.
57. Mackalski BA, Ilnyckyj A. Esophageal pH testing in patients refractory to proton pump inhibitor therapy. Can J Gastroenterol 2008; 22:249-252. (Pubitemid 351676385)
58. Bredenoord AJ, Smout AJ. Refractory gastrooesophageal reflux disease. Eur J Gastroenterol Hepatol 2008; 20:217-223.
59. Tutuian R, Vela MF, Hill EG, et al. Characteristics of symptomatic reflux episodes on acid suppressive therapy. Am J Gastroenterol 2008; 103: 1090-1096. A study of patients with persistent symptoms on acid suppressive therapy, who underwent combined impedance-pH monitoring, suggesting that reflux episodes extending proximally and having a mixed (liquid-gas) composition are significantly associated with symptoms, regardless of whether the reflux episodes are acidic or nonacid. (Pubitemid 351677992)
60. Emerenziani S, Sifrim D, Habib FI, et al. Presence of gas in the refluxate enhances reflux perception in nonerosive patients with physiological acid exposure of the oesophagus. Gut 2008; 57:443-447. This study performed 24 h esophageal pH-impedance monitoring in NERD and in esophagitis patients suggesting that in NERD patients, the presence of gas in the refluxate significantly enhances the risk of reflux perception.
61. Zerbib F, Duriez A, Roman S, et al. Determinants of gastro-oesophageal reflux perception in patients with persistent symptoms despite proton pump inhibitors. Gut 2008; 57:156-160. Ambulatory 24 h impedance-pH studies performed in patients with typical reflux symptoms despite b.i.d. PPIs suggested that high proximal extent of the refluxate is the only factor associated with reflux perception. (Pubitemid 351158039)
62. Sharma N, Agrawal A, Freeman J, et al. An analysis of persistent symptoms in acid-suppressed patients undergoing impedance-pH monitoring. Clin Gastroenterol Hepatol 2008; 6:521-524. A retrospective review of 200 patients on b.i.d. PPI with GERD symptoms during ambulatory impedance-pH testing.
63. Sharma P, Chey W, Hunt R, et al. Endoscopy of the esophagus in gastroesophageal reflux disease: are we losing sight of symptoms? Another perspective. Dis Esophagus (in press).
64. Hemmink GJ, Bredenoord AJ, Weusten BL, et al. Esophageal pH-impedance monitoring in patients with therapy-resistant reflux symptoms: 'on' or 'off' proton pump inhibitor? Am J Gastroenterol 2008; 103:2446-2453.
65. Aanen MC, Bredenoord AJ, Numans ME, et al. Reproducibility of symptom association analysis in ambulatory reflux monitoring. Am J Gastroenterol 2008; 103:2200-2208.
66. Chey WD, Mody R, Chen L, et al. Nighttime symptoms and sleep impairment among patients with gastro-esophageal reflux disease (GERD) receiving prescription (Rx) proton pump inhibitors (PPIs). Gastroenterology 2008; 134 (4 Suppl 1):A323-A324; Abstract #M1033.
67. Peghini PL, Katz PO, Bracy NA, Castell DO. Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. Am J Gastroenterol 1998; 93:763-767. (Pubitemid 29063918)
68. Galmiche JP, Zerbib F, Bruley des Varannes S. Review article: respiratory manifestations of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2008; 27:449-464.
69. Miehlke S, Madisch A, Kirsch C, et al. Intragastric acidity during treatment with esomeprazole 40mg twice daily or pantoprazole 40mg twice daily - a randomized, two-way crossover study. Aliment Pharmacol Ther 2005; 21:963-967. (Pubitemid 40529729)
70. Johnson DA, Katz PO. Nocturnal gastroesophageal reflux disease: issues, implications, and management strategies. Rev Gastroenterol Disord 2008; 8:98-108. (Pubitemid 351947609)
71. Tytgat GN, McColl K, Tack J, et al. New algorithm for the treatment of gastrooesophageal reflux disease. Aliment Pharmacol Ther 2008; 27:249-256.
72. Armstrong D, Talley NJ, Lauritsen K, et al. The role of acid suppression in patients with endoscopy-negative reflux disease: the effect of treatment with esomeprazole or omeprazole. Aliment Pharmacol Ther 2004; 20:413-421. (Pubitemid 39120252)
73. Khan M, Santana J, Donnellan C, et al. Medical treatments in the short term management of reflux oesophagitis. Cochrane Database Syst Rev 2007: CD003244.
74. Kahrilas PJ, Shaheen NJ, Vaezi MF, American Gastroenterological Association Institute; Clinical Practice and Quality Management Committee. American Gastroenterological Association Institute technical review on the management of gastroesophageal reflux disease. Gastroenterology 2008; 135:1392-1413; 1413e1-5
75. Targownik LE, Metge C, Roos L, Leung S. The prevalence of and the clinical and demographic characteristics associated with high-intensity proton pump inhibitor use. Am J Gastroenterol 2007; 102:942-950. (Pubitemid 46698226)
76. Targownik LE, Metge C, Leung S. Comparing resource utilization and gastrointestinal outcomes in patients treated with either standard-dose or high-dose proton pump inhibitors: a matched cohort study. Dig Dis Sci 2008; 53:1519-1526. (Pubitemid 351624416)
77. Fändriks L, Lönroth H, Pettersson A, Vakil N. Can famotidine and omeprazole be combined on a once-daily basis? Scand J Gastroenterol 2007; 42:689-694.
78. Mainie I, Tutuian R, Castell DO. Addition of a H2 receptor antagonist to PPI improves acid control and decreases nocturnal acid breakthrough. J Clin Gastroenterol 2008; 42:676-679.
79. Rackoff A, Agrawal A, Hila A, et al. Histamine-2 receptor antagonists at night improve gastroesophageal reflux disease symptoms for patients on proton pump inhibitor therapy. Dis Esophagus 2005; 18:370-373. (Pubitemid 43904763)
80. Fackler WK, Ours TM, Vaezi MF, Richter JE. Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough. Gastroenterology 2002; 122:625-632. (Pubitemid 34173813)
81. Hunt RH. Review article: the unmet needs in delayed-release proton-pump inhibitor therapy in 2005. Aliment Pharmacol Ther 2005; 22 (Suppl 3): 10-19.
82. Katz PO, Scheiman JM, Barkun AN. Review article: acid-related disease - what are the unmet clinical needs? Aliment Pharmacol Ther 2006; 23 (Suppl 2):9-22.
83. Vakil N. New pharmacological agents for the treatment of gastroesophageal reflux disease. Rev Gastroenterol Disord 2008; 8:117-122. (Pubitemid 351947611)
84. Scarpignato C, Hunt RH. Proton pump inhibitors: the beginning of the end or the end of the beginning? Curr Opin Pharmacol 2008; 8:677-684. A comprehensive review of the new developments and future therapy in the field of antisecretory drugs.
85. Hunt RH, Armstrong D, James C, et al. Effect on intragastric pH of a PPI with a prolonged plasma half-life: comparison between tenatoprazole and esome-prazole on the duration of acid suppression in healthy male volunteers. Am J Gastroenterol 2005; 100:1949-1956. (Pubitemid 43919386)
86. Hunt RH, Armstrong D, Yaghoobi M, et al. S-tenatoprazole-Na 30mg, 60mg, 90mg versus esomperazole (ESO) 40mg in healthy male volunteers (HMVs). Gastroenterology 2007; 132 (Suppl 2):A-488; Abstract #T1201.
87. Yuan Y, Chen Y, Hunt RH. Dose-effect of S-tenatoprazole-Na in healthy volunteers: a meta-analysis of individual subject data from four pharmacodynamic studies. Gastroenterology 2008; 134 (4 suppl 1):A176; Abstract #S1093.
88. Holzer P. Taste receptors in the gastrointestinal tract. Part V: Acid sensing in the gastrointestinal tract. Am J Physiol Gastrointest Liver Physiol 2007; 292:G699-G705. (Pubitemid 46440373)
89. Kahrilas PJ, Dent J, Lauritsen K, et al. A randomized, comparative study of three doses of AZD0865 and esomeprazole for healing of reflux esophagitis. Clin Gastroenterol Hepatol 2007; 5:1385-1391. (Pubitemid 350181597)
90. Dent J, Kahrilas PJ, Hatlebakk J, et al. A randomized, comparative trial of a potassium-competitive acid blocker (AZD0865) and esomeprazole for the treatment of patients with nonerosive reflux disease. Am J Gastroenterol 2008; 103:20-26.
91. Dent J. Pathogenesis of gastro-oesophageal reflux disease and novel options for its therapy. Neurogastroenterol Motil 2008; 20 (Suppl 1):91-102.
92. Lehmann A. Novel treatments of GERD: focus on the lower esophageal sphincter. Eur Rev Med Pharmacol Sci 2008; 12 (Suppl 1):103-110.
93. Grossi L, Spezzaferro M, Sacco LF, Marzio L. Effect of baclofen on oesophageal motility and transient lower oesophageal sphincter relaxations in GORD patients: a 48-h manometric study. Neurogastroenterol Motil 2008; 20:760-766. (Pubitemid 351814390)
94. Wang C, Hunt RH. Medical management of gastroesophageal reflux disease. Gastroenterol Clin North Am 2008; 37:879-899; ix.
95. Castell DO, Gerson LB, Hirota WK, et al. R-Baclofen prodrug XP19986 decrease reflux episodes and is well tolerated in GERD patients. Gastroenterology 2007; 132 (4 Suppl 2):A-486; Abstract #T1191.
96. Alstermark C, Amin K, Dinn SR, et al. Synthesis and pharmacological evaluation of novel gamma-aminobutyric acid type B (GABAB) receptor agonists as gastroesophageal reflux inhibitors. Med Chem 2008; 51:4315-4320. (Pubitemid 352032456)
97. Rodriguez-Stanley S, Zubaidi S, Proskin HM, et al. Effect of tegaserod on esophageal pain threshold, regurgitation, and symptom relief in patients with functional heartburn and mechanical sensitivity. Clin Gastroenterol Hepatol 2006; 4:442-450.
98. Abdulnour-Nakhoul S, Tobey NA, Nakhoul NL, et al. The effect of tegaserod on esophageal submucosal glands bicarbonate and mucin secretion. Dig Dis Sci 2008; 53:2366-2372.
99. Choung RS, Ferguson DD, Murray JA, et al. A novel partial 5HT3 agonist DDP733 after a standard refluxogenic meal reduces reflux events: a randomized, double-blind, placebo-controlled pharmacodynamic study. Aliment Pharmacol Ther 2008; 27:404-411.
100. Mayer MD, Vakily M, Witt G, Mulford DJ. The pharmacokinetics of TAK-390MR 60mg, a dual delayed release formulation of the proton pump inhibitor AK-390, and lansoprazole 60mg: a retrospective analysis. Gastroenterology 2008; 134 (Suppl 1):A-176; Abstract #S1095.
101. Zhang W, Wu J, Atkinson SN. Pharmacokinetics, pharmacodynamics, and safety evaluation of a single and multiple 60 mg, 90 mg, and 120 mg oral doses of modified release TAK-390 (TAK-390MR) and 30 mg oral dose of lansoprazole in healthy subjects. Gastroenterology 2007; 132 (suppl 52): A-487; Abstract #T1194.
102. Sharma P, Shaheen NJ, Perez MC, et al. Clinical trials: healing of erosive oesophagitis with dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed-release formulation - results from two randomized controlled studies. Aliment Pharmacol Ther 2009; 29:734-741.
103. Zhou Q, Yan XF, Pan WS, Zeng S. Is the required therapeutic effect always achieved by racemic switch of proton-pump inhibitors? World J Gastroenterol 2008; 14:2617-2619.
104. Andersson T, Weidolf L. Stereoselective disposition of proton pump inhibitors. Clin Drug Investig 2008; 28:263-279.
105. Bardan E, Nadler M, Navh M, et al. PPI enhancement with co-administration of oral parietal cell stimulator: a model for enhanced suppression of gastric acid secretion during the day and at night. Gastroenterology 2007; 132 (4 Suppl 2):A-488; Abstract #T1198.
106. Chowers Y, Atarot T, Kostadinov A, et al. PPI activity is optimized by VB 101, a parietal cell activator. Gastroenterology 2008; 134 (Suppl 1):A-172; Abstract #1076.